BioDelivery Sciences International, Inc. (BDSI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have earned an average rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $6.00.

BDSI has been the topic of several research reports. Cantor Fitzgerald set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Friday, February 15th. Janney Montgomery Scott reissued a “buy” rating and issued a $5.00 price target on shares of BioDelivery Sciences International in a research note on Thursday, January 31st. BidaskClub raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, January 11th. Finally, Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 11th.

NASDAQ:BDSI opened at $5.11 on Friday. The company has a current ratio of 3.07, a quick ratio of 2.82 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $362.57 million, a PE ratio of -7.00 and a beta of 0.45. BioDelivery Sciences International has a twelve month low of $1.70 and a twelve month high of $5.36.

In other news, Director Mark A. Sirgo sold 9,050 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $5.20, for a total value of $47,060.00. Following the sale, the director now directly owns 2,509,005 shares of the company’s stock, valued at approximately $13,046,826. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark A. Sirgo sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 27th. The shares were sold at an average price of $2.91, for a total transaction of $29,100.00. Following the completion of the sale, the director now directly owns 2,489,542 shares in the company, valued at $7,244,567.22. The disclosure for this sale can be found here. Insiders have sold 59,225 shares of company stock worth $262,325 over the last ninety days. 13.26% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in BDSI. Northern Trust Corp raised its stake in shares of BioDelivery Sciences International by 19.9% in the 2nd quarter. Northern Trust Corp now owns 191,016 shares of the specialty pharmaceutical company’s stock valued at $563,000 after acquiring an additional 31,749 shares during the period. Wells Fargo & Company MN raised its stake in shares of BioDelivery Sciences International by 121.7% in the 3rd quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock valued at $331,000 after acquiring an additional 64,803 shares during the period. JPMorgan Chase & Co. raised its stake in shares of BioDelivery Sciences International by 35.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 267,874 shares of the specialty pharmaceutical company’s stock valued at $750,000 after acquiring an additional 70,633 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of BioDelivery Sciences International in the 3rd quarter valued at approximately $255,000. Finally, Blair William & Co. IL raised its stake in shares of BioDelivery Sciences International by 11.5% in the 3rd quarter. Blair William & Co. IL now owns 787,845 shares of the specialty pharmaceutical company’s stock valued at $2,206,000 after acquiring an additional 80,975 shares during the period. 56.98% of the stock is currently owned by institutional investors and hedge funds.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Featured Story: How to track put option volume

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.